LL-341070

LL-341070 is an orally administered, brain-directed **small molecule thyromimetic prodrug** being developed by Autobahn Therapeutics for demyelinating diseases, particularly multiple sclerosis. It is designed to passively diffuse across the blood-brain barrier in a neutral form and then be converted in the brain by fatty-acid-amide-hydrolase to its active metabolite, LL-341070 A. The active species functions as a **thyroid hormone receptor beta agonist**, promoting oligodendrocyte maturation and remyelination to restore damaged myelin; preclinical studies have reported improvements in vision, motor function, and cognition in demyelination models, with activity described as superior to clemastine in certain remyelination assays.

Other names

LL-341070 ALL341070 ALL 341070 A